ESMO Virtual Congress 2020 Industry Satellite Symposium

IMMUNE CHECKPOINT BLOCKADE IN NON-MELANOMA SKIN CANCER

Available On Demand

from 09:00 CEST, Tuesday 22 September 2020


live Q&A

16:00–16:30 CEST, Saturday 26 September 2020

Educational objectives



Understand the current treatment of metastatic and locally advanced CSCC including the role of immuno-oncology



Understand the potential use of immune checkpoint inhibitors as adjuvant and neoadjuvant therapy in CSCC



Understand the unmet needs of patients with non-resectable BCC and how the use of immune checkpoint inhibitors can potentially address gaps in the treatment paradigm

Agenda

Time	Title	Speaker
5 mins	Welcome, introduction and objectives	Chrysalyne Schmults
25 mins	Treatment for locally advanced/metastatic cutaneous squamous cell carcinoma (CSCC)	Chrysalyne Schmults
25 mins	Exploring the emerging research with immuno-oncology in CSCC	Dirk Schadendorf
25 mins	Emerging research with immune checkpoint inhibitors in basal cell carcinoma (BCC)	Susana Puig
Sat 26 Sept 16:00–16:30	Live Q&A	All faculty

This is not a CME program. This non-promotional event sponsored by Sanofi Genzyme and Regeneron will include discussion of investigational products and products that may not be approved by the regulatory agency in your local country.